DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia.

Author(s): Chen F, Maridakis V, O'Neill EA, Hubbard BK, Strack A, Beals C, Herman GA, Wong P

Affiliation(s): Merck Research Laboratories, Rahway, NJ 07065-0900, USA. fabian_chen@merck.com

Publication date & source: 2011-06, Biomarkers., 16(4):321-33. Epub 2011 Mar 21.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

BACKGROUND: Lipidomic biomarkers will facilitate the development of novel anti-atherosclerotic therapies. OBJECTIVE: To evaluate the responses of circulating biomarkers to simvastatin treatment. METHODS: A randomized, cross-over study in men with mixed dyslipidaemia was used to compare effects of simvastatin 40 mg/day with placebo. RESULTS: Plasma concentrations of nine fatty acids (FA; of 33 evaluated) were reduced significantly by simvastatin. No changes in the rates of FA synthesis or in hepatic lipase or lipoprotein lipase activities were apparent. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased. CONCLUSION: We identified lipidomic biomarkers of simvastatin treatment effect that are consistent with statin inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase (ClinicalTrials.gov: NCT00935259).

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017